Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703560 | 0.98 | LMNA (0.33) | LMNASMN1; SMN2NAPRTEGFR | |
| SCHEMBL3699055 | 0.98 | LMNA (0.33) | LMNASMN1; SMN2NAPRTEGFR | |
| Hydrochloric Acid SCHEMBL28164000 | 0.98 | LMNA (0.33) | LMNASMN1; SMN2NAPRTEGFR | |
| SCHEMBL3707701 | 0.98 | LMNA (0.33) | LMNASMN1; SMN2NAPRTEGFR | |
| SCHEMBL2042500 | 0.80 | ALDH1A1 (0.33) | LMNASMN1; SMN2HSD17B10 | |
| SCHEMBL2449209 | 0.78 | CA1 (0.34) | LMNA | |
| SCHEMBL3703556 | 0.76 | MEN1 (0.33) | NFE2L2 | |
| Lithium Ion SCHEMBL3699053 | 0.76 | MEN1 (0.33) | NFE2L2 | |
| Potassium Ion SCHEMBL3707699 | 0.76 | MEN1 (0.33) | NFE2L2 | |
| SCHEMBL28502273 | 0.75 | NFE2L2 (0.43) | LMNASMN1; SMN2NAPRTKDM4ENFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116359391-A | Detection method of sulfonamide antibiotics in soil and sample treatment method thereof | 浙江省农业科学院 | 2023-06-30 | — | — | CN | disclosed |
| EP-2460789-B1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9079830-B2 | Method for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-2460789-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120123154-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123154-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | AKR7A2, AOC2, CBR1 | LMNA 3592/4885SMN1; SMN2 3565/4885NAPRT 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.